Medera Strengthens Leadership Team with Three Key Executive Appointments to Advance Cardiac Gene Therapy Pipeline
Key Insights
Medera Inc. (search) announced the appointment of three senior executives to strengthen its leadership team as the company advances its cardiac gene therapy programs through ongoing clinical trials.
The new appointments include Fubao Wang, Ph.D., as Chief Regulatory Officer and Chief Technical Officer at Sardocor (search), bringing over 28 years of pharmaceutical and biotech experience across gene therapy and regulatory affairs.
James Kim joins as Chief Corporate Officer with over 20 years of biopharmaceutical industry experience, having executed over 100 transactions totaling approximately $25 billion in financings and M&A deals.
Medera Inc. (search), a clinical-stage biopharmaceutical company focused on cardiovascular diseases (search), announced the appointment of three senior executives to strengthen its leadership team as the company advances its innovative cardiac gene therapy programs through ongoing clinical trials. The expanded team includes Fubao Wang, Ph.D., as Chief Regulatory Officer and Chief Technical Officer at Sardocor (search); James Kim as Chief Corporate Officer at Medera; and Niharika Kamat, M.S., as Vice President of Clinical Operations at Sardocor.
"These exceptional leaders bring decades of combined experience in gene therapy, clinical operations, regulatory affairs, and corporate finance that will be instrumental as we advance our innovative cardiac gene therapy programs through ongoing clinical trials," said Ronald Li, Ph.D., CEO and Co-Founder of Medera. "Their proven track records in bringing complex therapies from development through regulatory approval, combined with deep capital markets expertise, align perfectly with our mission to transform treatment for patients with incurable cardiovascular diseases (search)."
Strategic Leadership Additions
Fubao Wang Brings Extensive Regulatory Expertise
Dr. Wang brings over 28 years of pharmaceutical and biotech industry experience across multiple prophylactic and therapeutic areas and product modalities including gene editing, cell and gene therapy, RNA therapeutics, biologics, and vaccines. His product development and regulatory experience encompasses CMC, pre-clinical, early-stage, and late-stage clinical development, global regulatory strategy, submission, approval, and post-approval regulatory maintenance.
Dr. Wang served most recently as Senior Vice President, Head of Regulatory Affairs at Prime Medicine and AskBio, and previously as Vice President, Head of Regulatory CMC at Sarepta Therapeutics, Associate Vice President, US site head of CMC Dossiers at Sanofi, and Director of Global and Emerging Markets Regulatory Affairs at Merck (search). He holds a B.S. in Biology and M.S. in Microbiology from Nankai University, China; Ph.D. in Molecular Biology from University of Heidelberg, Germany, and was trained as a Post-Doctoral Fellow in Molecular Biology and Genetics at Stanford University.
James Kim Adds Corporate Finance Leadership
Mr. Kim brings over 20 years of experience in the biopharmaceutical industry as a senior executive and investment banker. In 2024, Mr. Kim served as Chief Financial Officer at TriArm Therapeutics (search), a private biotechnology company specializing in CAR-T therapies. Prior to his role at TriArm, Mr. Kim was a Managing Director at Stifel, Raymond James, Cantor Fitzgerald, and Jefferies, focused on biopharmaceutical coverage.
He has advised on and executed over 100 transactions, totaling approximately $13 billion in mezzanine, public equity, and debt financings, as well as $12 billion in business development and M&A transactions. Mr. Kim holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.
Niharika Kamat Strengthens Clinical Operations
Ms. Kamat brings nearly 20 years of leadership experience across the medical device, pharmaceutical, and biotechnology sectors, with deep expertise in global Phase 1-3 trials across cardiovascular, liver, hemophilia, and rare disease indications. Prior to joining Sardocor (search), she served as Head of Clinical Operations at Tenaya Therapeutics, where she led First-in-Human gene therapy trials in cardiovascular disease, implemented dose escalation strategies, and built a high-performing Clinical Operations team.
Her earlier roles include leading gene therapy programs for hemophilia at Catalyst Biosciences (search) and nearly a decade at Gilead Sciences managing small molecule trials across all phases in infectious diseases, as well as contributing to cardiovascular medical device development at Abbott Vascular. Ms. Kamat holds a Master's degree in Bioengineering from the University of Texas at Arlington and a Bachelor's degree in Biomedical Engineering from Mumbai University.
Advancing Cardiac Gene Therapy Pipeline
Sardocor (search), Medera's clinical development division, has received Investigational New Drug (IND) clearances from the FDA for three ongoing AAV-based cardiac gene therapy clinical trials targeting Heart Failure with Reduced Ejection Fraction (search) (HFrEF), Heart Failure with Preserved Ejection Fraction (search) (HFpEF) with the Fast Track Designation, and Duchenne Muscular Dystrophy-associated Cardiomyopathy (search) (DMD-CM) with the Orphan Drug Designation. Additionally, Sardocor's pipeline includes four preclinical gene therapy and three preclinical small molecule candidates targeting various cardiac, pulmonary, and vascular diseases.
The company operates through two business units: Novoheart (search), which capitalizes on the world's first and award-winning "mini-Heart" Technology for revolutionary disease modeling and drug discovery, and Sardocor (search), dedicated to clinical development of novel next-generation therapies. Novoheart's versatile technology platform provides state-of-the-art automation hardware and software as well as screening services for human-specific disease modeling, therapeutic target discovery and validation, drug toxicity and efficacy screening, and dosage optimization carried out in the context of healthy and diseased human heart chambers and tissues.
With these strategic leadership appointments, Medera strengthens its position to advance its pipeline of innovative cardiac gene therapies while building the regulatory, clinical operations, and corporate expertise necessary to bring these potentially transformative treatments to patients with significant unmet medical needs.